| |
n = 60 (%)
|
|---|
|
Age
|
< 60
|
28 (46.7%)
|
|
≥ 60
|
32 (53.3%)
|
|
Sex
|
Female
|
12 (20.0%)
|
|
Male
|
48 (80.0%)
|
|
ECOG performance status
|
0
|
9 (15.0%)
|
|
1
|
51 (85.0%)
|
|
Pathologic confirmation
|
No
|
0 (0.0%)
|
|
Yes
|
60 (100%)
|
|
Child-Pugh classification
|
A5
|
41 (68.3%)
|
|
A6
|
19 (31.7%)
|
|
Etiology
|
Hepatitis B
|
46 (76.7%)
|
|
Hepatitis C
|
6 (10.0%)
|
|
Alcohol
|
1 (1.7%)
|
|
Primary biliary cirrhosis
|
1 (1.7%)
|
|
Others
|
6 (10.0%)
|
|
Alpha-fetoprotein
|
≥ 400
|
30 (50.0%)
|
|
< 400
|
30 (50.0%)
|
|
Extrahepatic disease
|
No
|
8 (13.3%)
|
|
Yes
|
52 (86.7%)
|
|
Prior treatment
|
Transplantation
|
0 (0.0%)
|
|
Surgery
|
17 (28.3%)
|
|
Locoregional therapy (RFA, TACE)
|
41 (68.3%)
|
|
Radiotherapy
|
31 (51.7%)
|
|
Prior chemotherapy
|
1
|
48 (80.0%)
|
|
≥ 2
|
12 (20.0%)
|
|
Prior sorafenib
|
No
|
0 (0.0%)
|
|
Yes
|
60 (100%)
|
- ECOG, Eastern Cooperative Oncology Group; RFA, radiofrequency ablation; TACE, transarterial chemoembolization
